Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

about

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

P2860

Q57824724-8EC132D8-2C75-4A2C-9A90-3F90CF2213A1

P2860

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

Item

http://www.wikidata.org/entity/Q40041609

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

@en

type

Item

label

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

@en

prefLabel

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

@en

P1476

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma

@en

P2093

Riccardo Haupt

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Identification of ALK as a major familial neuroblastoma predisposition gene

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Defining the role of mTOR in cancer

The TOR pathway: a target for cancer therapy

The MYCN oncoprotein as a drug development target.

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.

Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study.

P304

1281-1293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1380625

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mirco Ponzoni

Alberto Garaventa

Loredana Amoroso

P577

2017-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28906153

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

about

P2860

P2860

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921